601794 Disclosed are ({ 5-[Benzyloxy]pyridin-2-yl} oxy)benzene derivatives as represented by the general formula (1), wherein R1 and R2 are each independently aryl or unsaturated heterocyclic ring, each of which is optionally substituted with one or more substituents； A is alkylene； Ring X is an optionally substituted arylene； E is bond or alkenylene； ring Y is an optionally substituted heterocycloalkylene containing one or more nitrogen atoms, one of which is attached to the adjacent carbonyl group； G is -NH-G2-, -N(alkyl)-G2-, -NH-CH2-G2-, -N(alkyl)-CH2-G2- or -CH2-G2-； wherein G2 of said G binds to R2； G2 is bond, phenylene-G3-, phenylene-G4-O-, phenylene-G5-NH-, phenylene-G6-N(alkyl)- or quinolinediyl-O-, wherein the phenylene of said phenylene-G3-, phenylene-G4-O-, phenylene-G5-NH- and phenylene-G6-N(alkyl)- is optionally substituted with one or more substituents selected from the group consisting of halogen and lower alkyl； G3 is bond, -O-alkylene-, alkylene-O-alkylene- or -O-alkylene-CO-； G4 is a bond, alkylene, alkenylene, -O-alkylene or -CO-alkylene-； and G5 and G6 are each alkylene. Representative compounds include (2E)-3-[4-({ 5-[(4-methoxybenzyl)oxy]pyridin-2-yl} oxy)-3,5-dimethylphenyl]-1-(4-{ 4-[(1E)-3-(4-methylphenoxy)prop-1-en-1-yl]benzyl} piperazin-1-yl)prop-2-en-1-one, (E)-3-[3-chloro-5-methyl-4-({ 5-[(4-methylbenzyl)oxy]pyridin-2-yl} oxy)phenyl]-1-[4-(4-{ 2-[4-(propan-2-yl)phenoxy]ethyl} benzyl)-1,4-diazepan-1-yl]prop-2-en-1-one, (E)-1-[4-(4-{ 2-[(4-chlorobenzyl)oxy]ethyl} benzyl)piperazin-1-yl]-3-(3,5-dimethyl-4-{ [5-(pyridin-4-ylmethoxy)pyridin-2-yl]oxy} phenyl)prop-2-en-1-one, (E)-3-[3-chloro-5-methyl-4-({ 5-[(4-methylbenzyl)oxy]pyridin-2-yl} oxy)phenyl]-2-methyl-1-(4-{ 4-[2-(4-methylphenoxy)ethyl]benzyl} piperazin-1-yl)prop-2-en-1-one hydrochloride, 4-({ [6-(2-fluoro-4-{ (E)-3-oxo-3-[4-(4-{ 2-[4-(propan-2-yl)phenoxy]ethyl} benzyl)piperazin-1-yl]prop-1-en-1-yl} phenoxy)pyridin-3-yl]oxy} methyl)benzonitrile hydrochloride and (E)-3-[3-chloro-5-me
